BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Riboxx Pharmaceuticals and China National Biotech Group Initiate a Collaboration to Evaluate the Potential of Riboxxim®, a TLR3 Agonist, as Adjuvant in a Vaccine to Treat a Deadly Infectious Disease


3/5/2013 11:16:42 AM

Radebeul, Germany and Beijing, China, March 5, 2013 / B3C newswire / – Riboxx Pharmaceuticals GmbH (Riboxx) and China National Biotec Group Company Limited (CNBG) today announced that they have initiated a research collaboration to evaluate Riboxxim®, a TLR3 agonist from Riboxx, with an antigen of CNBG against one of the world’s deadliest infectious diseases.

During the term of the research collaboration, Riboxx will provide access to Riboxxim® to enable CNBG to perform an evaluation in conjunction with CNBG’s antigen against the disease target.

Dr. Jacques Rohayem, CEO of Riboxx said: “We are delighted to initiate this collaboration with CNBG, which is one of the leading developers of vaccines against serious infectious diseases. Our TLR3 agonist has the potential to increase the efficacy of the antigen and provide a safe but highly effective immune response against the disease.”

Xie Guilin, Vice President of CNBG said: “The collaboration with Riboxx is designed to evaluate the potential of Riboxxim as an effective adjuvant to enhance the performance of our antigen. This combination has the potential to deliver effective immunization against a deadly disease that is inadequately treated at present.”

About Riboxx Pharmaceuticals GmbH

Riboxx Pharmaceuticals GmbH is a company focused on the development of molecules targeted to Toll-like Receptors (TLRs), with a direct application as vaccine adjuvants. The company engineers and manufactures Riboxxim, agonists of TLR-3, to the highest possible quality standards. Today, Riboxx has on-going collaborations with both academic and industrial partners to advance the application of Riboxxim in vaccination and immunotherapy. The company is headquartered in Radebeul, Germany.

About Riboxxim

The proprietary TLR3 agonist of Riboxx, Riboxxim®, is a class of synthetic, highly pure and precisely defined nucleic acids molecules manufactured by TENPORA®, a proprietary process of Riboxx. These molecules are capable of triggering innate immune responses through TLR-3 activation, enabling novel immunization approaches both in prophylactic vaccines (e.g. against infections) and in therapeutic vaccines (e.g. against cancer).

About CNBG

China National Biotec Group Company Limited (CNBG), is a subsidiary of China National Pharmaceutical Group Corporation (SINOPHARM). As the first manufacturer of vaccines and blood products in China and with 6 Biological Products Institutes in house, they have been devoted to the research, development, production and supply of biological products since 1919. The development of CNBG Corporation represents the history of Chinese biological products industry. In the past century, they made great contribution in China’s endeavor of eradiating smallpox, eliminating polio, reducing the incidence of various serious infectious diseases, supplied billions of doses of vaccines and therapeutic biological to the country, thus, and safeguarding the health of the world’s largest population.

For Further Information, please contact:

Riboxx GmBH

Dr. Jacques Rohayem

Founder and CEO

T: +49 351 833 6010

E: Jacques.rohayem@riboxx.com

CNBG

Dr. Xie Guilin

Vice President

T: +86-10-84663377

E: xieguilin@cnbg.com.cn



Read at BioSpace.com
Read at ChinaBio Today

 
 
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->